Johnson & Johnson (JNJ) Receivables - Net (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Receivables - Net came in at $17.7 billion in Q1 2026, up 10.62% year-on-year from $16.0 billion in Q1 2025, and up 3.16% quarter-over-quarter from $17.2 billion in Q4 2025.
Johnson & Johnson (JNJ) Receivables - Net (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Receivables - Net across 18 years of filings, most recently posting $17.7 billion for Q1 2026.
- Receivables - Net for Q1 2026 came in at $17.7 billion, up 10.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.7 billion (up 10.62% YoY), and the FY2025 annual result was $17.2 billion, up 15.74% from the prior year.
- Receivables - Net came in at $17.7 billion for Q1 2026 at Johnson & Johnson, up from $17.2 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $17.8 billion in Q2 2025 to a low of $14.0 billion in Q1 2023.
- The 5-year median for Receivables - Net is $16.0 billion (2022), against an average of $16.0 billion.
- Across the five-year window, Receivables - Net retreated 8.59% in 2024 and advanced 15.74% in 2025, its largest moves.
- Johnson & Johnson's Receivables - Net stood at $15.9 billion in 2022, then decreased by 6.4% to $14.9 billion in 2023, then fell by 0.21% to $14.8 billion in 2024, then grew by 15.74% to $17.2 billion in 2025, then gained by 3.16% to $17.7 billion in 2026.
- The last three Receivables - Net figures came in at $17.7 billion (Q1 2026), $17.2 billion (Q4 2025), and $17.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 17.72 Bn |
| Mar 29, 2026 | 17.72 Bn |
| Dec 28, 2025 | 17.18 Bn |
| Dec 28, 2025 | 17.18 Bn |
| Sep 28, 2025 | 17.61 Bn |
| Sep 28, 2025 | 17.61 Bn |
| Jun 29, 2025 | 17.85 Bn |
| Jun 29, 2025 | 17.85 Bn |
| Mar 30, 2025 | 16.02 Bn |
| Mar 30, 2025 | 16.02 Bn |
| Dec 29, 2024 | 14.84 Bn |
| Dec 29, 2024 | 14.84 Bn |
| Sep 29, 2024 | 16.17 Bn |
| Sep 29, 2024 | 16.17 Bn |
| Jun 30, 2024 | 15.79 Bn |
| Jun 30, 2024 | 15.79 Bn |
| Mar 31, 2024 | 14.95 Bn |
| Mar 31, 2024 | 14.95 Bn |
| Dec 31, 2023 | 14.87 Bn |
| Dec 31, 2023 | 14.87 Bn |